... WhatsApp

Diabetes Drug Linked to Better Survival in Women with Endometrial Cancer

You are here >> Home > Latest Updates > Uterus Cancer > Diabetes Drug…

Diabetes Drug Linked to Better Survival in Women with Endometrial Cancer

Endometrial cancer starts in the lining of the uterus. It is often linked to obesity and type 2 diabetes. Many women with this cancer also take medicines for diabetes. One type of diabetes drug, called sodium-glucose cotransporter-2 inhibitors (SGLT2i), may do more than just control blood sugar.

Researchers looked at health records from women in the United States who had endometrial cancer between 2014 and 2023. They compared two groups: women who used SGLT2i and women who did not. Each group had more than 2,000 patients, and the researchers made sure both groups were similar in age, health conditions, and other medicines.

The study found that women taking SGLT2i had much better survival. About 8 out of 100 women who used these drugs died, compared with 21 out of 100 women who did not use them. This means SGLT2i use was linked to about half the risk of death. The survival benefit was seen in women of different ages, weights, and health conditions, including those with diabetes, heart failure, or kidney disease.

Importantly, the drugs did not increase serious side effects like kidney failure, infections, or sepsis. This suggests they may be a safe option for women with both diabetes and endometrial cancer.

This research does not prove that SGLT2i directly treats cancer, but it shows promise. Doctors may consider these drugs as part of diabetes care in women who also have endometrial cancer. More studies are needed to confirm these findings, but the results give hope for better outcomes.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.